JN.1 COVID Doctor Home Visit NYC, NJ, Miami, & Texas  

Book a home visit and get
40% off Glutathione IV.

JN.1 COVID Doctor Home Visit NYC,
NJ, Miami, & Texas  

$225 Medical House-call Fee

Board Certified Physician Assistants,
Nurse Practitioners and Registered Nurses
with Physician oversight of all visits.

7+ years providing Concierge Services from Urgent Care Injuries and
Sick Visits to Wellness IV's and Physicals
All our providers are supervised by an MD
We are in: NYC NJ, MIAMI, FL & TEXAS.

Fact: leaa health is the first company in America
to manage COVID in the house
And do home COVID testing; pretty cool, ha:)


your info 
30-60 min responce time

NYC Home
Urgent care

Primary and preventive health care.
IV medications.
Wellness IV.
Complex symptom management.
In Home Palliative Care.
Medical Diagnosis.
Treatment of medical conditions.
Prescription of medications, and delivery.
Support to family members.

We are in: NY, LONG ISLAND, NJ,

A message from leaa

"People will buy a custom suit and car, but what about custom medical care? Why settle for medical care off the rack? Your life is more important than any suit or car, don't take a chance on your life; we only have one life to live."

Understanding COVID NJ.1

19 Variant JN.1 As the world continues to fight back against the ongoing COVID-19 pandemic, new variants of the virus continue to emerge, fueling the spread of the disease and thwarting efforts to end it. One such variant that has captured the attention of scientists and health professionals is the JN.1 strain of the virus. The JN.1 variant, first detected towards the end of 20

21, is a reminder of the adaptability and volatility of the COVID-19 virus. Although less publicized than the Alpha, Beta, or Delta variants, JN.1 offers unique insights into the evolving landscape of this global health crisis. Known as the 'Japanese variant' due to its initial emergence in Japan, JN.1 has since been identified in several other countries. The variant exhibits a set of mutations in the spike protein of the virus — the component the virus uses to bind to human cells and initiate infection. The existence of these mutations has sparked concerns about the variant's potential implications for public health. These concerns primarily revolve around two issues: vaccine effectiveness and transmission rates. On the subject of vaccines, extensive studies are ongoing to understand whether existing vaccines provide adequate protection against JN.

1. The primary concern is that the variant's altered spike protein could impact the ability of antibodies, generated in response to vaccination or previous infection, to neutralize the virus. As of now, the World Health Organization (WHO) and several health agencies have not identified JN.1 as a 'variant of concern' or a 'variant of interest,' categories which signify an increased threat to public health.

This cautious approach signifies that while potential risks exist, extensive surveillance and research is necessary to determine the precise nature of these risks. In terms of transmissibility, preliminary data suggests that the JN.1 variant could potentially spread more efficiently than earlier strains of the virus. However, it's critical to note that definitive conclusions about the variant's transmissibility remain unconfirmed as the research is still ongoing.

The discovery and monitoring of new COVID-19 variants like JN.1 underscore the importance of a robust and responsive global surveillance system. Regular genomic sequencing and prompt sharing of these findings internationally are indispensable tools in monitoring the virus' evolution and developing effective countermeasures. Furthermore, this serves as a reminder that the fight against COVID-19 is far from over. As long as the virus continues to spread, it will be able to mutate, potentially compromising our current resources and strategies.

This underlines the global urgency for equitable vaccine distribution, reinforcement of public health measures like mask-wearing and social distancing, and continued investments in vaccine research and development. In conclusion, while the JN.1 variant of COVID-19 is currently under investigation, it is a stark reminder of the virus's ability to adapt and the potential challenges new variants can pose.

To stay one step ahead, the world needs to remain vigilant, flexible, and committed to the strategies that have proven effective in containing the virus's spread: mass vaccination, the practice of safety measures, increased testing, and genomic surveillance. Article 600/600. Note: The details contained in this article are based on the state of knowledge about the JN.1 variant as of its writing and are subject to change as further research is conducted.

Our story
how it all started


We all deserve safe and high-quality medical services 
call leaa today for all your health and wellness needs, all in the comfort of your home.

More about leaa
Fact: leaa health is the first company in America
to manage COVID in the house
And do home COVID testing; pretty cool, ha:)

Trusted Medical House Call Service in
NY, Nj, FL, and Houston TX.
Over 80 doctors ready to visit you.

Medical Providers On Demand Home Visits LEAA EST 2017© Copyright
The Content On This Website Is Copyright Protected All Rights Reserved.
The services provided have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. The material on this website is provided for informational and educational purposes only and is not medical advice. Always consult your physician before beginning any therapy program. Prices and services subject to change at any time. Since this is a medical service, no refunds are issued.